Objective: To investigate the effect of Campath-1H induction on immunosuppression in small intestine transplantation.
Methods: Clinical data of a patient who underwent small intestine transplantation were retrospectively summarized.
Results: Intraoperative Campath-1H induction by intravenous injection was administered. Triple immunosuppression(FK506, MMF and methylprednisolone) was used postoperatively. The lymphocyte and leukocyte decreased significantly following Campath-1H induction, and returned to normal after adjusting the dose of immunosuppressant and use of colony stimulating factor. There were no acute rejection, graft versus host disease, or severe infection during the immediate postoperative period. The patient recovered and discharged.
Conclusion: Intraoperative Campath-1H induction and postoperative triple immunosuppression using FK506, MMF, and methylprednisolone may prevent rejection and graft versus host disease in the early stage after small intestine transplantation.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Alemtuzumab Associated With Higher Mortality Than Basiliximab in Older Kidney Transplant Recipients.
J Surg Res
December 2024
Comprehensive Transplant Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Introduction: Kidney transplantation (KT) in older age is increasingly common as more elderly patients live with end-stage renal disease. Immunosuppression (IS) after KT confers additional risk in aging patients with weakened immune systems. We hypothesized that 1-year mortality among KT recipients aged 70 y and older would be higher in those receiving induction IS with alemtuzumab lymphocyte depletion versus basiliximab interleukin-2 inhibition.
View Article and Find Full Text PDFOutcomes of Older Primary Kidney Transplant Recipients by Induction Agent and High-risk Viral Discordance Status in the United States.
Transplant Direct
October 2024
Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN.
Article Synopsis
- The study investigates how the type of induction therapy and high-risk viral discordance affect outcomes in kidney transplant recipients over the age of 55.
- It analyzes data from over 87,000 transplant cases between 2005 and 2022, focusing on three induction types: rabbit antithymocyte globulin (r-ATG), interleukin-2 receptor antagonist (IL-2RA), and alemtuzumab.
- Results indicate that while induction type didn't impact recipient survival, high-risk Epstein-Barr virus discordance increased mortality, and alemtuzumab was linked to a higher risk of graft loss compared to r-ATG.
Rapamycin Prevents Expansion of Costimulation Blockade-resistant CD8+ Alloreactive Memory Cells following Depletional Induction in Renal Transplant Recipients.
J Immunol
November 2024
Department of Surgery, Duke University School of Medicine, Durham, NC.
Alemtuzumab induction with belatacept/rapamycin-based maintenance immunotherapy (ABR) prevents kidney allograft rejection and specifically limits early costimulation blockade-resistant rejection (CoBRR). To evaluate the mechanisms by which this regimen alters CoBRR, we characterized the phenotype and functional response of preexisting memory cells to allogeneic endothelial cells using intracellular cytokine staining and flow cytometry. IL-7-induced lymphocyte proliferation in the presence or absence of rapamycin was assessed to characterize the phenotype of proliferating cells.
View Article and Find Full Text PDFOcrelizumab in MS patients with persistence of disease activity after alemtuzumab: A multi-center Italian study.
Mult Scler
August 2024
IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Background: The reason why some multiple sclerosis (MS) patients show disease activity after alemtuzumab (ALM) is still unclear, but ocrelizumab (OCR) could represent an interesting sequential therapeutic approach.
Objectives: To investigate safety and efficacy of OCR in MS patients with disease activity after two ALM courses.
Methods: Observational retrospective multi-centers Italian cohort study.
Induction immunosuppression strategies and outcomes post-lung transplant: A single center experience.
Transpl Immunol
August 2024
Department of Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, FL, United States of America. Electronic address:
Purpose: Currently 80% of lung transplant centers use induction immunosuppression. However, there is a lack of standardization of induction protocols within and across lung transplant centers. This study explores the association of two different induction immunosuppression strategies used at our center [single dose rabbit antithymocyte globulin (rATG) vs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!